Pages that link to "Q80981297"

The following pages link to Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response (Q80981297):

Displaying 44 items.

• Rituximab for rheumatoid arthritis (Q24186568) (← links)
• Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series (Q24647924) (← links)
• Humoral-targeted immunotherapies in multiple sclerosis (Q26865971) (← links)
• A New-Age for Biologic Therapies: Long-Term Drug-Free Therapy with BiP? (Q28730158) (← links)
• Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium (Q33399862) (← links)
• B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients (Q33706447) (← links)
• A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis (Q33731743) (← links)
• Progressive multifocal leukoencephalopathy and other forms of JC virus disease (Q33763351) (← links)
• Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab (Q33798060) (← links)
• Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR) (Q34056237) (← links)
• Epstein-Barr virus in bone marrow of rheumatoid arthritis patients predicts response to rituximab treatment. (Q34117122) (← links)
• Targeting the B Cell in Rheumatoid Arthritis (Q34622760) (← links)
• CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells (Q34688644) (← links)
• Rituximab-associated interstitial lung disease in fibrillary glomerulonephritis (Q35626535) (← links)
• Rituximab mediates loss of CD19 on B cells in the absence of cell death (Q36252683) (← links)
• Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series. (Q36265388) (← links)
• B lymphocyte-typing for prediction of clinical response to rituximab (Q36633292) (← links)
• A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis (Q37030703) (← links)
• Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy (Q37075975) (← links)
• Spontaneous bacterial peritonitis from Salmonella: an unusual bacterium with unusual presentation (Q37278235) (← links)
• B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis (Q37586921) (← links)
• The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials (Q37754083) (← links)
• Synovial tissue response to treatment in rheumatoid arthritis (Q37978861) (← links)
• Rituximab therapy in nephrotic syndrome: implications for patients' management (Q38075787) (← links)
• Indications of rituximab in autoimmune diseases (Q39925216) (← links)
• The assay design used for measurement of therapeutic antibody concentrations can affect pharmacokinetic parameters: Case studies (Q41123234) (← links)
• A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis (Q41449525) (← links)
• NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab (Q42020570) (← links)
• Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis? (Q42633541) (← links)
• Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children (Q47864240) (← links)
• Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis (Q50014741) (← links)
• Relapse of nephrotic syndrome during post-rituximab peripheral blood B-lymphocyte depletion (Q50707874) (← links)
• Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy (Q51007604) (← links)
• Safety and patient response as indicated by biomarker changes to binding immunoglobulin protein in the phase I/IIA RAGULA clinical trial in rheumatoid arthritis. (Q51588372) (← links)
• Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD. (Q55442184) (← links)
• The humanized anti-HLA-DR moAb, IMMU-114, depletes APCs and reduces alloreactive T cells: implications for preventing GVHD (Q82152061) (← links)
• Response to rituximab and timeframe to relapse in rheumatoid arthritis patients: association with B-cell markers (Q82730683) (← links)
• Therapeutic protein-drug interactions and implications for drug development (Q83120849) (← links)
• Expression of NK (CD16+56+) and B cells (CD19) Receptor Molecules as a Reliable Clinical Response Biomarkers of SLE and RA Patients Under the Rituximab Treatment (Q89819345) (← links)
• Immune Response Following Quadrivalent Human Papillomavirus Vaccination in Women After Hematopoietic Allogeneic Stem Cell Transplant: A Nonrandomized Clinical Trial (Q89915009) (← links)
• Single-Cell Analysis Suggests that Ongoing Affinity Maturation Drives the Emergence of Pemphigus Vulgaris Autoimmune Disease (Q92147757) (← links)
• Non-response to rituximab therapy in rheumatoid arthritis is associated with incomplete disruption of the B cell receptor repertoire (Q92882806) (← links)
• A Randomized, Double-Blind Study Comparing Pharmacokinetics and Pharmacodynamics of Proposed Biosimilar ABP 798 With Rituximab Reference Product in Subjects With Moderate to Severe Rheumatoid Arthritis (Q97081764) (← links)
• Integrated mechanistic model of minimal residual disease kinetics with venetoclax therapy in chronic lymphocytic leukemia (Q98199298) (← links)